Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 8/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29790987 | 1.00 | KCNH2 (0.46) | KCNH2 | |
| SCHEMBL15800504 | 0.97 | KCNH2 (0.43) | KCNH2 | |
| SCHEMBL3642604 | 0.90 | CHRM2 (0.47) | KCNH2 | |
| SCHEMBL4133761 | 0.87 | CTNNB1 (0.43) | — | |
| SCHEMBL24502844 | 0.84 | KCNH2 (0.44) | KCNH2 | |
| SCHEMBL17030555 | 0.84 | CTNNB1 (0.40) | — | |
| SCHEMBL10157959 | 0.78 | KCNH2 (0.49) | KCNH2 | |
| SCHEMBL31061889 | 0.78 | KCNH2 (0.49) | KCNH2 | |
| SCHEMBL14079587 | 0.78 | KCNH2 (0.46) | KCNH2 | |
| SCHEMBL28841074 | 0.78 | KCNH2 (0.46) | KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090048224-A1 | COMPOUNDS AND METHODS OF USE | AMGEN, INC. (US) | 2009-02-19 | — | — | US | disclosed |
| US-7425631-B2 | Compounds and methods of use | AMGEN INC. (US) | 2008-09-16 | — | — | US | disclosed |
| US-7199244-B2 | Cyclic amine derivatives and methods of use | AMGEN (US) | 2007-04-03 | — | — | US | disclosed |
| EP-1633743-A1 | CYCLIC AMINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF INFLAMMATION-RELATED DISORDERS MEDIATED BY BRADYKININ | Amgen, Inc. (US) | 2006-03-15 | — | — | EP | disclosed |
| EP-1631542-A1 | BICYCLIC COMPOUNDS HAVING BRADYKININ RECEPTORS AFFINITY AND PHARMACEUTICAL COMPOSITIONS THEREOF | Amgen, Inc. (US) | 2006-03-08 | — | — | EP | disclosed |
| US-20050234044-A1 | Cyclic amine derivatives and methods of use | AMGEN INC. | 2005-10-20 | — | — | US | disclosed |
| US-20050124654-A1 | Compounds and methods of use | AMGEN INC. | 2005-06-09 | — | — | US | disclosed |
| WO-2004092116-A1 | BICYCLIC COMPOUNDS HAVING BRADYKININ RECEPTORS AFFINITY AND PHARMACEUTICAL COMPOSITIONS THEREOF | AMGEN, INC. (US) | 2004-10-28 | — | — | WO | disclosed |
| WO-2004092164-A1 | CYCLIC AMINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF INFLAMMATION-RELATED DISORDERS MEDIATED BY BRADYKININ | AMGEN, INC. (US) | 2004-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050124654-A1 | Compounds and methods of use | LTC4S, PTGES, LTB4R2 | KCNH2 2702/4885 |
| US-20090048224-A1 | COMPOUNDS AND METHODS OF USE | LTC4S, PTGES, LTB4R2 | KCNH2 2702/4885 |
| US-20050234044-A1 | Cyclic amine derivatives and methods of use | PTGIS, BDKRB2, LTC4S | KCNH2 1601/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.